Validation of claims-based diagnoses of adult and pediatric neuromyelitis optica spectrum disorder and variations in diagnostic evaluation and treatment initiation.

[1]  J. Lechner-Scott,et al.  Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. , 2019, Multiple sclerosis and related disorders.

[2]  Mhs,et al.  Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder , 2019 .

[3]  Jacqueline Palace,et al.  Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. , 2019, The New England journal of medicine.

[4]  F. Paul,et al.  MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. , 2018, Multiple sclerosis and related disorders.

[5]  M. Sepúlveda,et al.  Antibodies in acquired demyelinating disorders in children , 2016, Multiple Sclerosis and Demyelinating Disorders.

[6]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[7]  Jacqueline Palace,et al.  Demographic and clinical features of neuromyelitis optica: A review , 2015, Multiple sclerosis.

[8]  M. Etemadifar,et al.  Epidemiology of Neuromyelitis Optica in the World: A Systematic Review and Meta-Analysis , 2015, Multiple sclerosis international.

[9]  M. Boggild,et al.  The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom , 2013, Journal of Neurology.

[10]  K. Kyvik,et al.  A population-based study of neuromyelitis optica in Caucasians , 2011, Neurology.

[11]  S. Olindo,et al.  Relapsing neuromyelitis optica: long term history and clinical predictors of death , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  J. Kurtzke,et al.  An epidemiological study of neuromyelitis optica in Cuba , 2009, Journal of Neurology.

[13]  B. Weinshenker,et al.  Revised diagnostic criteria for neuromyelitis optica , 2006, Neurology.